drugset
drugset / Trial / NCT04871594

Pre-operative Immunotherapy in Stage II-III Urothelial Cancer

NCT04871594 ↗

Phase 1 Completed 15 enrolled The Netherlands Cancer Institute 4SC AG · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 1b feasibility study of pre-operative immunotherapy in PD-L1 positive resectable stage II-III urothelial cancer patients. This study can be adapted or expanded based on the results obtained.

Timeline

Start
2021-08-23
Primary completion
2023-06-02
Completion
2024-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Nivolumab Monoclonal antibody 240 mg —

Indications

urothelial carcinoma